Agency Business briefs

Share this article:
Baer Consulting launched RxED, a boutique shop dedicated to patient education and advocacy relations. The new agency, located at Baer Headquarters, is led by Baer Consulting founder Michele Baer, plus Sharon Savel and Cathy Lewis-Fink, both of The Eden Communications Group.

Porter Novelli hired former Pfizer Exec Barbara DeBuono as the agency's chief medical officer, global director of public health and social marketing, a newly created position. At Pfizer, DeBuono was executive director, public health and government.

Loomis Group Health, an independent marketing agency, announced a partnership with Capella Advisors to provide healthcare companies with strategic planning, commercialization and other marketing programs in support of new products targeted to consumers. Loomis has done work for Abbott, Elan and Medtronic in the past, according to a company statement.

CommonHealth opened an office in Tokyo—CommonHealth Kyowa. CommonHealth has had a working relationship with Kyowa Kikaku, a sister WPP shop, since 1997. The office will be managed locally by Kazuo Okuhara.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?